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Sustained, targeted, high-level transgene expression 
in primary B lymphocytes may be useful for gene ther-
apy in B cell disorders. We developed several candidate 
B-lineage predominant self-inactivating lentiviral vectors 
(LV) containing alternative enhancer/promoter elements 
including: the immunoglobulin β (Igβ) (B29) promoter 
combined with the immunoglobulin μ enhancer (EμB29); 
and the endogenous BTK promoter with or without Eμ 
(EμBtkp or Btkp). LV-driven enhanced green fluorescent 
protein (eGFP) reporter expression was evaluated in cell 
lines and primary cells derived from human or murine 
hematopoietic stem cells (HSC). In murine primary cells, 
EμB29 and EμBtkp LV-mediated high-level expression in 
immature and mature B cells compared with all other 
lineages. Expression increased with B cell maturation 
and was maintained in peripheral subsets. Expression in 
T and myeloid cells was much lower in percentage and 
intensity. Similarly, both EμB29 and EμBtkp LV exhibited 
high-level activity in human primary B cells. In contrast to 
EμB29, Btkp and EμBtkp LV also exhibited modest activ-
ity in myeloid cells, consistent with the expression profile 
of endogenous Bruton’s tyrosine kinase (Btk). Notably, 
EμB29 and EμBtkp activity was superior in all expression 
models to an alternative, B-lineage targeted vector con-
taining the EμS.CD19 enhancer/promoter. In summary, 
EμB29 and EμBtkp LV comprise efficient delivery plat-
forms for gene expression in B-lineage cells.
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IntroductIon
B cells represent an important target for gene transfer because 
single gene defects impacting B-lineage function have significant 
roles in the pathogenesis of immunodeficiency and autoimmu-
nity.1 One B cell disorder predicted to benefit from safe strategies 
for gene delivery is X-linked agammaglobulinemia (XLA). XLA is 
an immunodeficiency caused by a recessive gene defect in Bruton’s 
tyrosine kinase (Btk),2 that results in a block in B cell development 
at the pro-B cell stage, reduced numbers of circulating B cells, and 
a near absence of antibody responses in affected males.3 XLA is a 
good candidate for gene therapy for several reasons: a relatively 
high disease frequency, the ability to treat without interruption 
of clinical therapy, and a strong selective advantage for gene-
 corrected cells.4,5 In order to facilitate such therapies, we focused 
on designing a lentiviral vector (LV) optimized to drive gene 
expression in primary B cells, with a special emphasis on vectors 
that mimic the expression profile of endogenous Btk.
Self-inactivating LVs (LV) comprise a promising gene delivery 
platform for treatment of genetic disorders, autoimmune diseases, 
and malignancies. In contrast to γ-retroviruses, LVs proficiently 
target nondividing cells such as multipotent hematopoietic stem 
cells (HSC) at low viral copy number.6–8 Self-inactivating-LV also 
limit the risk of viral long-terminal repeat enhancer mutagenesis 
and concurrently permit the use of lineage-specific promoters.9 
Furthermore, there is evidence of less transcriptional silencing of 
internal promoters within integrated LV, and a reduced bias for 
integration near transcription start sites.10 These combined fea-
tures likely reduce the overall risk of viral enhancer-mutagene-
sis responsible for adverse events in several γ-retroviral clinical 
trials.11,12 Previous work has demonstrated efficient transgene 
expression with LV utilizing a range of internal promoter and 
other regulatory elements.8,13,14
To decrease potential side effects of nonspecific transgene 
expression in HSC-derived lineages, various vectors have been 
designed to restrict transgene expression to one or several lin-
eages. For example, specific regulatory elements have been used 
for targeted expression within erythroid, T, antigen-presenting and 
myeloid cells, respectively.15–18 Notably, Moreau et al. showed that 
LV incorporating the regulatory sequences from the human CD19 
promoter allowed preferential transgene expression in B-lineage 
cells.19 Importantly, addition of the immunoglobulin heavy chain 
μ intronic enhancer (Eμ) and its associated matrix attachment 
regions both significantly increased gene expression and promoted 
uniformity of expression compared with either the PGK20 or CD19 
minimal promoters alone.21,22 However, the levels of expression 
obtained with the B-restricted LV reported to date are low in com-
parison with that mediated by promiscuous γ-retroviral-derived 
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enhancer/promoter elements. Thus, it has remained unclear as to 
whether candidate B cell-specific LV will mediate transgene expres-
sion at levels that will restore function in B-lineage disorders, an 
important consideration as low levels of B-lineage Btk expression 
is insufficient to rescue murine models of XLA.23,24
In the studies described here, we sought to design LVs that will 
mimic the expression pattern of endogenous Btk, with the ultimate 
goal of utilizing such constructs for gene therapy in XLA patients. 
We generated LV containing three alternative B cell-specific internal 
enhancer/promoters and evaluated their ability to drive enhanced 
green fluorescent protein (eGFP) reporter gene expression. As a 
reference point, we compared the specificity of expression driven 
by these elements to a previously described B cell-specific LV, EμS.
CD19.21 In parallel, each was compared to a LV containing a strong 
murine leukemia virus-derived, enhancer/promoter, myeloprolif-
erative sarcoma virus enhancer, negative control region deleted, 
dl587rev primer-binding site substituted (MND), capable of driving 
high-level transgene expression in all hematopoietic lineages,25 and 
used in a recent successful LV clinical trial.14 LVs were compared with 
respect to relative expression in cell lines and primary murine and 
human cells at low viral copy number. We found that both EμB29 
and EμBtkp LV preferentially direct high-level, sustained, transgene 
expression in immature and mature B lymphoid cells, and support 
future testing of these constructs in XLA gene therapy models.
results
design of B-lineage targeted lV
As shown schematically in Figure 1, we generated a number of 
LV-containing alternative enhancer/promoter elements within 
the parental pRRL backbone.9 The first, MND-eGFP, incorporated 
a ubiquitous, γ-retroviral enhancer/promoter. In comparison to 
other mammalian-derived ubiquitous elements such as elonga-
tion factor 1α or PGK, MND drives much higher expression lev-
els in primary murine and human cells providing a benchmark 
for very high-level gene expression (data not shown). Second, we 
generated a construct equivalent to the previously reported, B 
cell-specific vector, EμS.CD19,19 comprised of the minimal CD19 
promoter (230 bp) in conjunction with the Eμ enhancer. While it 
has been reported that inclusion of a larger portion of the CD19 
promoter element (1,274 bp—designated EμL.CD19) generates 
higher expression levels in B cells, we found little difference in 
expression levels between these promoters when in association 
with Eμ (Supplementary Figure S1a). Next, we generated EμB29-
eGFP LV, which contains the B29 (Igβ, CD79b) minimal promoter 
element26 in association with the murine immunoglobulin heavy 
chain, intronic enhancer, Eμ.27 B29, a key signaling component of 
the B cell antigen receptor, is initially expressed in pro-B cells and 
its expression increases in immature/mature B cells.26,28,29 Because 
the B29 promoter alone exhibited only low-level basal expression 
(data not shown), the Eμ enhancer was added to increase activ-
ity in maturing B cells. The total size of the enhancer/promoter 
elements for EμB29 and EμS.CD19 were nearly identical. Finally, 
we created two unique LV constructs designated Btkp-eGFP and 
EμBtkp-eGFP, that contain regulatory elements derived from the 
human BTK locus either alone or in combination with the Eμ 
enhancer, respectively. The 37 kb BTK locus is comprised of 19 
exons at Xq22.30,31 Transcriptional start sites of human Btk were 
previously identified within −5 and −30 bp of exon 1 with a mini-
mal promoter critical for lineage-restricted expression between 
−200 and −1 bp from the transcriptional start site.32–34 Additional 
reporter studies implicated putative regulatory elements between 
−450 and −200, as well as two conserved NF-κB binding sites 
within −800 to −600, as positive regulators of Btk expression.35 
We therefore used the first 788 bp of the Btk promoter including 
these elements, hypothesizing that Btkp, in conjunction with the 
Eμ enhancer, might provide strong B cell-predominant expression 
and also retain endogenous control elements essential for lineage-
appropriate Btk expression.
eµB29 lV drives B-lineage predominant expression 
that increases with cell maturation
We first compared the expression of eGFP driven by EμB29, EμS.
CD19, and MND LV in human T (Jurkat), myeloid (K562), and 
B cell lines including a panel of different B developmental stages: 
pro-B (REH), pre-B (Blin and Nalm6), immature B (Ramos), and 
mature B (Raji) cells. Transduction rates were adjusted via matching 
eGFP marking to ~10–15% in order to evaluate expression medi-
ated by mostly single viral-integration. In this setting, eGFP mean 
fluorescent intensity (MFI) provides a direct measure of relative 
promoter strength. Compared to MND, both EμB29 and EμS.CD19 
LV exhibited B cell-predominant eGFP expression with the highest 
expression levels in more mature B cell lines (Figure 2). Importantly, 
eGFP MFI was significantly higher in all B cell lines transduced 
with EμB29 compared to EμS.CD19 LV; with the  greatest expres-
sion in lines representative of mature stages, e.g., Ramos and Raji 
B cells. Substitution of the extended CD19 promoter (to generate 



















Figure 1  schematic of lentiviral constructs. LV were constructed using 
a pRRL backbone containing an enhancer-deleted U3 region to generate 
a self-inactivating (SIN) LTR and differ only in their internal promoter/
enhancer region. MND is a retroviral LTR-derived ubiquitous promoter 
that drives transgene expression in most hematopoietic lineages. Both 
EμS.CD19-eGFP and EμL.CD19-eGFP employ regulatory sequences from 
human CD19 and EμB29-eGFP utilizes a murine B29 minimal promoter. 
Btkp-eGFP LV and EμBtkp-eGFP LV contain a788 bp element derived 
from endogenous human BTK locus (described in Materials and Methods 
section). EμB29, EμS.CD19, EμL.CD19, and EμBtkp each also include the 
murine immunoglobulin intronic enhancer, Eμ. Btk, Bruton’s tyrosine 
kinase; eGFP, enhanced green fluorescent protein; LV, lentiviral vec-
tors; LTR, long-terminal repeats; MND, myeloproliferative sarcoma virus 
enhancer, negative control region deleted, dl587rev primer-binding site 
substituted; wPRE, woodchuck hepatitis virus posttranscriptional regula-
tory element.
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EμL.CD19 LV) resulted in slightly higher levels of eGFP compared 
with EμS.CD19 LV (Supplementary Figure S1a). However, the 
expression level for both constructs remained significantly lower 
than EμB29 LV (Supplementary Figure S1b).
eµB29 drives high-level eGFP expression in primary 
murine B-lymphocytes
To assess expression and lineage specificity in vivo, congenically 
marked, B6.Ly5.1 recipient mice were lethally irradiated and trans-
planted with B6.Ly5.2, Lin− HSC transduced with either: MND-
eGFP; EμS.CD19-eGFP; or EμB29-eGFP LV. Mice with donor 
chimerism of >90% were sacrificed 25 weeks post-transplant and 
spleen and bone marrow (BM) cells analyzed for relative eGFP 
expression in myeloid and lymphocyte subsets (Figures 3 and 4). 
Figure 3a,b shows representative data from a single experiment 
(3–5 recipients/group). Of note, the MFI of eGFP expression 
across independent experiments was influenced by differences 
in the instrument used for analysis and/or the voltage settings of 
the laser used to detect eGFP (488 nm argon). While this limited 
our ability to present a combined dataset, we observed consistent 
relative differences among our panel of LV constructs in multiple 
experiments. For comparison, the results from a second indepen-
dent experiment are displayed in Figure 3c and representative flu-
orescence-activated cell sorting (FACS) plots comparing B-lineage 
promoter activity for EμB29 versus EμS.CD19 LV from both 
experiments are shown in Supplementary Figure S2. Analysis of B 
cells, T cells, neutrophils and macrophages revealed expression by 
in all lineages. eGFP MFI, however, was markedly lower in non-B 
versus B cells. EμB29 LV exhibited up to fivefold higher eGFP MFI 
in B cells compared to all other lineages (Figure 3d). Furthermore, 
although both LV lead to B cell-predominant expression, nearly all 
EμB29 recipients exhibited approximately fourfold higher MFI in 
B cells compared with EμS.CD19 (Figure 3b,c). One EμB29 recip-
ient animal (in experiment #1) exhibited eGFP expression levels 
similar to that present in EμS.CD19 recipients; and this result cor-
related with the lowest viral copy number among the eight EμB29 
animals shown. By comparison, MND LV exhibited similar, albeit 
variable, eGFP expression in all lineages. Average viral copy num-
bers were similar in all LV cohorts (Figure 3e) indicating that dif-
ferential LV promoter activity did not reflect altered transduction 
efficiency.
We next determined whether LV-mediated expression 
was modulated during BM and/or peripheral B cell develop-
ment and selection (Figure 4). Figure 4a shows representative 
FACS plots of eGFP expression in developing BM B cells. The 
subsets of developing B cells were gated-based CD43, IgM and 
IgD expression as described in the figure legend. eGFP MFI 
was significantly higher in all BM B cells derived from EμB29-
eGFP compared to EμS.CD19-eGFP recipients (Figure 4a) and 
increased as cells matured from the pro- to mature B cell stage 
in EμB29 LV recipients (Figure 4b). In contrast, there was little 
or no change in eGFP MFI in EμS.CD19-eGFP recipients and 
MND-eGFP recipients exhibited greater variability with a trend 
for reduced expression in mature cells. Splenic transitional 1 and 
2 (T1 and T2), follicular mature, and marginal zone/marginal 
zone precursor B cells were identified based on of CD21 and 
CD24 expression within B220+ B cells36 and eGFP expression in 
each subset determined (Figure 4c). Most MND-eGFP LV recip-
ients exhibited a decline, and EμS.CD19 LV recipients little or no 
change, in relative eGFP MFI in immature versus more mature 
B cells, respectively. In contrast, the majority of EμB29-LV 
recipients exhibited a consistent increase in eGFP MFI in more 
mature, follicular mature, and marginal zone/marginal zone 
precursor, compared to less mature, T1 B cells. Thus, EμB29-LV 
drives high-level B predominant expression that increases with 
B cell maturation.
eµB29 mediates high-level B-lineage expression  
in primary human B-lymphocytes
We also examined the activity of candidate LV in primary human 
cells derived from transduced HSC. We utilized a NOD/SCID/
γc−/− (NSG) xenograft system in which MND-eGFP, EμS.CD19-
eGFP or EμB29-eGFP LV transduced human cord blood CD34+ 
cells were transplanted into recipient immune-deficient NSG 
mice.37,38 Engrafted mice were sacrificed at 20–25 weeks post-
 transplant and human-derived, BM and splenic hematopoietic 
subsets were analyzed for relative eGFP expression (Figure 5). 
The level of human cell engraftment in each mouse is depicted 
as the percentage of DAPI-live cells that express the human 
leukocyte common antigen marker CD45 (Figure 5b). A large 
percentage of splenic CD45+ cells were CD19+ B cells similar 
to other reports using the NSG model. Moderate populations of 
CD4+ and CD8+ T cells, as well as CD33+ myeloid cells, were 
also identified in all recipients. MND LV drove high-level eGFP 
expression in all  lineages. In contrast, EμS.CD19 and EμB29 lead 






























Figure 2 eµB29 exhibits increased levels of transgene expression 
compared to eµs.cd19 in B cell lines. A panel of human cell lines was 
transduced with MND-eGFP (gray bars), EμS.CD19-eGFP (black bars) or 
EμB29-eGFP (striped bars) LV to achieve 10–15% eGFP marking. Cells 
were evaluated on day 4 for eGFP expression by FACS. B cell lines selected 
were derived from a representative of different developmental stages: REH 
(pro-B), Blin or Nalm6 (pre-B), Ramos (immature B), and Raji (mature B). 
Expression was also compared using Jurkat (T) and K562 (myeloid) cell 
lines. Data shows mean fluorescence intensity (MFI) of eGFP in each line 
based upon three experiments. *indicate statistically significant results 
in this and all subsequent figures, with *<0.05, **<0.01 and ***<0.001. 
Only the statistically significant data is highlighted in this manner. eGFP, 
enhanced green fluorescent protein; FACS, fluorescence-activated cell 
sorting; MND, myeloproliferative sarcoma virus enhancer, negative con-
trol region deleted, dl587rev primer-binding site substituted.
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Figure 3 eµB29 drives high-level, B cell-predominant, transgene expression in primary murine B cells. Lin− BM cells were isolated from congeni-
cally marked Ly5.1 B6 mice, transduced with MND-eGFP, EμS.CD19-eGFP, or EμB29-GFP LV at an MOI of 10 for 6 hours and 1 × 106 transduced cells 
transplanted into lethally irradiated Ly5.2 B6 recipients. Twenty-five weeks post-transplantation, mice were sacrificed and splenic cells were stained for 
B220, CD4, CD8, CD11b, GR1, Ly5.1, and Ly5.2 to identify donor B cells (B220+), T cells (CD4+ or CD8+), neutrophils (B220−CD4−CD8−CD11b+GR1+) 
and monocytes (B220−CD4−CD8−CD11b+GR1−). (a) Representative FACS plots showing eGFP expression in splenic-derived lineages in one mouse 
per condition. Numbers indicate MFI for eGFP+ cells. (b) Graphs display eGFP MFI for each lineage in all mice from the experiment shown in (a) (2–5 
mice/group). (c) Graphs show eGFP MFI for each lineage in all mice from a second independent experiment (3–4 mice/group). (d) Graphical repre-
sentation of the ratio of eGFP expression in T cells, myeloid cells or neutrophils verses B cells. (e) Viral copy number in spleen cells. Combined data 
in d–e are derived from experiments shown in b and c. BM, bone marrow; Btk, Bruton’s tyrosine kinase; eGFP, enhanced green fluorescent protein; 
FACS, fluorescence-activated cell sorting; LV, lentiviral vectors; LTR, long-terminal repeats; MFI, mean fluorescent intensity; MND, myeloproliferative 
sarcoma virus enhancer, negative control region deleted, dl587rev primer-binding site substituted; MOI, multiplicity of infection.
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to B cell-predominant eGFP expression with lower expression in 
T and myeloid cells (Figure 5b–d). Although substantial varia-
tion was observed among individual recipients, the average level 
of eGFP expression in B cells was fourfold higher for EμB29 com-
pared to EμS.CD19 LV. Viral copy numbers were similar in all 
experimental groups (Figure 5e).
The cell surface marker, CD10, is expressed specifically on 
immature human B cells.39 We therefore evaluated relative eGFP 
expression in immature CD10+ versus more mature CD10− CD19+ 
BM B cells in recipient NSG mice. EμB29-eGFP LV recipients 
exhibited a progressive increase in eGFP MFI in CD10− com-
pared to CD10+ B cells (Figure 6a). In contrast, little difference 
was observed in EμS.CD19 recipients, and MND LV recipients 
exhibited a decline in eGFP MFI in CD10− cells. Immature, splenic 
CD24hiCD38hi B cells in NSG recipients also express CD10,40 con-
sistent with the presence of recent BM emigrant B cells. Splenic 
B cells in EμB29-eGFP LV recipients exhibited a similar increase 
in eGFP MFI in mature CD10− compared to immature CD10+ B 
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Figure 4 eµB29 facilitates higher transgene expression during B cell maturation. BM from chimeras described in Figure 3 were stained with 
antibodies against B220, CD43, IgM, IgD, Ly5.1 and Ly5.2 and B cell subsets were identified as: CD43hiIgM−IgD− (pro-B); CD43loIgM−IgD− (pre-
B); CD43−IgM+IgDlo (immature); CD43−IgM+IgDint (transitional); and CD43−IgM+IgDhi (mature) B cells. (a) FACS plots show representative MFI of 
eGFP in BM B cell subsets from one mouse per condition. Numbers in each plot show MFI for eGFP+ cells. (b) Graphs showing relative MFI of eGFP 
in B cell subsets in all mice from one experiment (3–6 mice per group). Data shown are representative of two independent experiments. (c) Splenic 
B220+ B cells were subdivided into developmental subsets based upon CD21 and CD24 expression (as in left panel) identify transitional 1 (T1), 
transitional 2 (T2), follicular mature (FM), and marginal zone/marginal zone precursors (MZ-MZP) B cells. MFI of eGFP expression in each subset is 
shown for individual mice transduced with each LV. BM, bone marrow; Btk, Bruton’s tyrosine kinase; eGFP, enhanced green fluorescent protein; FACS, 
fluorescence-activated cell sorting; Ig, immunoglobulin; LV, lentiviral vectors; MFI, mean fluorescent intensity; MND, myeloproliferative sarcoma virus 
enhancer, negative control region deleted, dl587rev primer-binding site substituted.
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cells (Figure 6b) whereas no increase in transgene expression was 
observed in EμS.CD19 or MND LV recipients. Together, these data 
demonstrate that EμB29 LV mediate high-level B predominant 
expression in primary human B cells and that expression increases 
with B-lineage maturation.
eµBtkp lV mediates high-level expression primary B 
cells as well as modest activity in myeloid subsets
LV containing key endogenous regulatory elements may provide 
improved safety with regard to nonspecific transgene expression.41 
Thus, based upon the potential goal of treating the B-lineage 
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Figure 5 eµB29 drives high-level, lineage predominant eGFP expression in primary human B cells. Human cord blood CD34+ cells were trans-
duced with MND-eGFP, EμS.CD19-eGFP, or EμB29-eGFP LV and transplanted into irradiated NSG recipient mice. Engrafted recipients were sacrificed 
20 weeks after transplantation for analysis of human cells. Spleen cells were stained with CD45 to identify human cells with hematopoietic subsets 
defined as B cells (B220+CD4−CD8− CD33−), T cells (B220−CD4+ or CD8+, CD33−), and myeloid cells (B220−CD4−CD8−CD33+), respectively. 
(a) Representative FACS plots showing eGFP expression in splenic populations from one mouse per condition. Numbers show MFI for eGFP+ cells. 
(b) Level of human cell engraftment in the spleen depicted as the percentage of live (DAPI−) cells that express the human leukocyte antigen, CD45. 
(c) Graph showing MFI of eGFP in human hematopoietic subsets with data from three experiments (7–8 mice per vector). (d) Graphs showing rela-
tive fold change in MFI levels between eGFP− and eGFP+ cells with data pooled from four experiments. (e) Graphical representation of the ratio of 
eGFP expression in T versus B cells or myeloid verse B cells. (f) Viral copy number in spleen cells. BM, bone marrow; Btk, Bruton’s tyrosine kinase; 
eGFP, enhanced green fluorescent protein; FACS, fluorescence-activated cell sorting; Ig, immunoglobulin; LV, lentiviral vectors; MFI, mean fluorescent 
intensity; MND, myeloproliferative sarcoma virus enhancer, negative control region deleted, dl587rev primer-binding site substituted.
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immune disorder, XLA, we generated LV containing regulatory 
elements derived from the human BTK locus. As described above 
(Figure 1), we generated Btkp and EμBtkp LV and compared 
these constructs with our best-performing, B-lineage expression 
vector, EμB29 LV, in murine and human-based in vivo models. 
First, we established mouse BM chimeras using HSC transduced 
with EμB29-eGFP, Btkp-eGFP, or EμBtkp-eGFP LV using the 
same methods as Figure 3. Recipient mice were sacrificed at 25 
weeks post-transplant and the relative percentage and intensity 
of eGFP expression assessed within various BM (data not shown) 
and splenic populations (Figure 7). As in Figure 3, due to dif-
ferences in the 488-nm argon laser voltage settings, the results 
from two independent experiments are shown (Figure 7b,c). 
Again, while overall eGFP MFI differed between experiments, we 
observed consistent results with respect to the panel of LV vectors. 
Representative FACS plots for both experiments are also shown in 
Supplementary Figure S2 (as experiment #3 and 4, respectively). 
EμBtkp LV-mediated high-level eGFP expression in splenic B 
cells, although by comparison EμB29 LV showed a slightly higher 
MFI in most animals (Figure 7a–c). In contrast, expression in 
B cells using Btkp LV was tenfold lower level than Eμ enhancer 
containing LV. As anticipated, only low-level eGFP expression 
was present in T cells. Consistent with its lower activity in B cells, 
the relative T:B cell expression ratio was ~0.35 (approximately 
threefold less) for Btkp versus ~0.05 (~20-fold less) for EμBtkp 
and EμB29 (Figure 7d). Consistent with the expression pattern 
of endogenous Btk, Btkp LV mediated similar levels of eGFP in 
B and myeloid cells. This feature was most evident when the MFI 
of eGFP in monocytes or neutrophils was analyzed as a ratio rela-
tive to the MFI in B cells (Figure 7d). The monocyte:B and the 
neutrophil:B expression ratios for Btkp LV were close to 1.0. An 
increase in myeloid expression ratio was also evident, albeit to a 
lesser degree, with EμBtkp when compared to EμB29 LV. In con-
trast, EμB29 expressed eGFP at significantly lower levels in mono-
cytes or neutrophils versus B cells. All recipient animals exhibited 
similar viral copy numbers (Figure 7e).
To assess LV function in human primary cells, cord blood 
CD34+ HSC were transduced with EμB29-eGFP, Btkp-eGFP, 
or EμBtkp-eGFP LV and transplanted into NSG recipient mice. 
Overall, the expression pattern in splenic-derived human cells 
mirrored those from the murine chimeric setting (Figure 8). 
EμBtkp LV drove high-level eGFP expression in human B cells 
whereas in Btkp LV eGFP expression was at least fivefold lower. 
Combined data from several experiments showed high-level, 
albeit variable, B cell expression for both EμB29 and EμBtkp LV 
(Figure 8b). T cell expression was very low in all recipients with a 
B:T cell expression ratio as high as 60 in some EμBtkp recipients. 
In contrast to EμB29, EμBtkp LV also led to intermediate levels of 
transgene expression in monocytes. However, because expression 
was variable this data did not reach statistical significance for the 
number of animals studied. As in murine studies, Btkp LV exhib-
ited consistent, low-level eGFP expression in both B cells and 
monocytes. All recipient animals exhibited similar average viral 
copy numbers (Figure 8c).
Collectively, these data demonstrate that EμBtkp LV mediates 
high-level transgene expression in primary murine and human 
B cells, presumably facilitated by the Eμ element; and also drives 
intermediate levels of transgene expression in myeloid cells in a 
manner analogous to the endogenous Btk promoter.
dIscussIon
Successful LV-based HSC gene therapy requires efficient gene trans-
fer into multipotent HSC followed by sustained, therapeutic levels 
of transgene expression within key target cell populations. This 
study focused on developing LV that facilitate gene expression in 
developing and mature B-lineage cells for use in candidate B-lineage 
disorders. Our data demonstrate efficient, B cell-predominant gene 
expression using LV vectors containing two distinct promoter/
enhancer combinations. Our initial studies focused on the com-
posite vector, EμB29. This construct mediated high-level reporter 
transgene expression in multiple human B cell lines and in both 
human and mouse primary B cells derived from transduced HSC. In 
contrast to previous observations showing highly variable B-lineage 
expression following HSC transduction using γ retroviral vectors,42 
cell differentiation did not lead to appreciable evidence for silenc-
ing or variegation of EμB29 LV. Consistent with this interpretation, 
sustained eGFP expression was observed in both immature and 
mature B cells for at least 20 weeks despite low-level viral marking 


































Figure 6 eµB29 drives higher eGFP expression in mature versus 
immature human B cells. Splenic and BM cells were isolated from NSG 
recipients as shown in Figure 5. Cells were stained with CD45 and 
CD19 to identify engrafted human B cells and with CD10 to distinguish 
immature (CD10+) versus more mature (CD10−) B cells. (a–b) Graphs 
showing change in MFI of eGFP in immature versus mature B cells 
derived from (a) BM or (b) spleen in mice from one experiment (3–4 
mice per group). Data shown are representative of one of three indepen-
dent experiments. BM, bone marrow; eGFP, enhanced green fluorescent 
protein; MFI, mean fluorescent intensity; MND, myeloproliferative sar-
coma virus enhancer, negative control region deleted, dl587rev primer-
binding site substituted.
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levels of reporter gene expression than EμS.CD19 LV, even though 
both LV contained minimal promoters activated at nearly identical 
points following B-lineage commitment. EμB29 LV expression also 
increased progressively in parallel with BM B cell differentiation in 
both murine and human models and was maintained in the periph-
eral B lymphoid compartment. Expression levels were further 
increased during splenic transitional development, leading to high-
est expression within mature murine marginal zone and  follicular 


















T cells Monocytes Neutrophils





























b Monocytes NeutrophilsB cells T cellsExp#1
N = 4 N = 3 N = 3
























N = 2 N = 3 N = 3
Exp#2c



























































































21,815 1,117 911 856
2,063 2,47376914,744
1,613 488 1,589 1,808
Figure 7 eµBtkp drives high-level eGFP expression in primary murine B cells and also exhibits modest activity in myeloid cells. Mouse BM chi-
meras were generated, as in Figure 3, using Lin− cells transduced with EμB29-eGFP, EμBtkp-eGFP, or Btkp-eGFP LV. Recipient animals were sacrificed 
25 weeks after transplantation. (a) Representative FACS plots showing eGFP expression in splenic populations. Numbers indicate MFI for eGFP+ cells. 
(b) Graphs display eGFP MFI for splenic subsets in all animals from the experiment shown in a (3–4 mice per group). (c) Graphs show eGFP MFI all 
animals from a second independent experiment (2–3 mice per group) (d) Graphical representation of the ratio of eGFP MFI in T cells, monocytes, or 
neutrophils versus B cells. (e) Viral copy number in spleen cells. Combined data shown in d–e are derived from experiments shown in b and c. BM, 
bone marrow; Btk, Bruton’s tyrosine kinase; eGFP, enhanced green fluorescent protein; FACS, fluorescence-activated cell sorting; LV, lentiviral vectors; 
MND, myeloproliferative sarcoma virus enhancer, negative control region deleted, dl587rev primer-binding site substituted.
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mature B cells, and CD10− human B cells, respectively. By con-
trast, EμS.CD19 LV exhibited lower level, stable expression levels 
throughout BM and peripheral B cell development.
Together these data suggest that EμB29 LV might be useful for 
clinical disorders where progressively higher levels of transgene 
expression are required in developing and mature B cells. Although 
we observed some variability in expression levels of eGFP driven 
by EμB29 LV in both the murine and human stem cell models, 
the overall trend for higher-level transgene expression (compared 
to EμS.CD19) suggests that this promoter would be a superior 
choice for B cell-specific expression. Notably, previous work has 
shown that subendogenous Btk expression levels are insufficient 
to mediate functional rescue of mature B cells Btk-deficient 
mice.23,24 Based on these ideas, we recently evaluated ex-vivo gene 
therapy in a murine model of XLA using the EμB29 LV to deliver 
human Btk. This approach lead to near-complete developmental 
and functional B cell rescue.43 Importantly, our findings paralleled 
earlier work from our group using a highly active,  ubiquitously 
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Figure 8 eµBtkp drives high-level transgene expression in primary human B cells and also exhibits activity in myeloid cells. Human cord blood 
CD34+ cells were transduced with EμB29-eGFP, EμBtkp-eGFP, or Btkp-eGFP LV and transplanted into irradiated NSG recipient mice (as in Figure 6). 
Engrafted recipients were sacrificed 20 weeks after transplantation for analysis. (a) Representative FACS plots showing eGFP expression in splenic 
cells with numbers indicating MFI in eGFP+ cells. (b) Level of human cell engraftment in the spleen. (c) Graphs showing relative fold change in MFI 
levels between eGFP− and eGFP+ cells in CD45+ human hematopoietic subsets (data pooled from four experiments) (d) Relative viral copy number 
in spleen cells in three experimental cohorts. BM, bone marrow; Btk, Bruton’s tyrosine kinase; eGFP, enhanced green fluorescent protein; FACS, 
fluorescence-activated cell sorting; LV, lentiviral vectors; MFI, mean fluorescent intensity; MND, myeloproliferative sarcoma virus enhancer, negative 
control region deleted, dl587rev primer-binding site substituted.
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expressed, murine stem cell virus-based γ retroviral vector.5 Thus, 
equivalent clinical efficacy was achieved via this unique B-lineage 
targeted, potentially safer, LV delivery platform.
Despite its efficacy in the murine XLA model, the EμB29 
enhancer/promoter may not be ideal for cell-specific Btk expres-
sion. Notably, while its functional role is most evident in B cells, Btk 
is also expressed in all myeloid subsets and megakaryocytes; and 
Btk also impacts signaling via a range of cell surface receptors.3,44 
Recent work has demonstrated a requirement for Btk kinases in 
Toll-like receptor signals45–47 implying that Btk deficiency may 
impact innate, as well as adaptive, immune responses in vivo. Based 
on these considerations, we generated LV constructs containing 
the endogenous BTK promoter. As anticipated, Btkp LV exhibited 
sustained, albeit low-level activity in primary murine and human 
B and myeloid cells. Importantly, addition of the Eμ enhancer lead 
to a marked increase in relative B-lineage expression, with activ-
ity levels closely mimicking EμB29 LV in both murine and human 
primary B cells. In contrast to EμB29 LV, however, EμBtkp LV also 
retained modest transgene expression in myeloid populations sug-
gesting this LV may more faithfully mimic endogenous Btk expres-
sion and potentially rescue Btk-dependent myeloid activity.
Taken together, our data indicate that EμB29 LV provides an 
efficient platform for high-level mammalian B cell gene expres-
sion. Furthermore, these data also suggest that EμBtkp LV may 
represent an optimal system for regulated Btk gene delivery in 
XLA. This latter possibility is currently being investigated using 
murine models of XLA. Finally, it is important to note that we 
observed no evidence for Eμ enhancer-dependent mutagenesis in 
this study or in >200 primary/secondary/or tertiary recipient mice 
treated to date using these LV for Btk delivery. Formal studies, 
however, using genome targeted integration48 and BM immortal-
ization assays49 will be required to more fully address the potential 
risk(s) of these new LV constructs.
MaterIals and Methods
LV constructs and viral production. The parental pRRL-SIN-cppt-PGK-
eGFP-WPRE vector9 was obtained from Didier Trono (Addgene plasmid 
#12252) and the internal PGK promoter was replaced to generate pRRL-
EµB29-eGFP, pRRL-EμBtkp-eGFP, pRRL-MND-eGFP, or pRRL-EµCD19-
eGFP. MND is a retroviral long-terminal repeats-derived promoter.50 The 
immunoglobulin μ heavy chain enhancer Eµ is comprised of the 1-kb 
murine Ig heavy chain intronic core enhancer and the 5′ and 3′ matrix 
attachment region elements27 and was added to all other promoters except 
MND and Btkp alone. B29 contained the minimal promoter element 
derived from the B29 gene comprising 184 bp of the murine promoter 
including −166 to +18 from the major transcriptional start site.26 S.CD19 
and L.CD19 contained the minimal (204 bp) versus extended (1,224 bp), 
human CD19 promoter element and adjacent upstream enhancer region, 
respectively.19 Btkp contains a 788 bp sequence located directly upstream 
of exon 1 within the human BTK locus. LV were produced by transient 
transfection of 293T cells using PEI method, concentrated by low-speed 
centrifugation, and titered as described previously.43
Cell culture and transduction. The following cell lines were utilized for 
lentiviral transduction experiments; Blin and Nalm6 (gift from Dr Tucker 
LeBien, University of Minnesota, Minneapolis, MN), REH, Ramos, Raji, 
Jurkat, and K562 (ATCC, Manassas, VA). All cells were maintained in 
complete RPMI (RPMI plus l- glutamine, 10% fetal bovine serum, 0.1% 
β-mercaptoethanol and 10 μmol/l HEPES) media and transduced with the 
indicated lentiviral construct overnight with 4 μg/ml polybrene at variable 
multiplicity of infection’s to obtain similar transduction rate (from 10 to 
15%). Cells were incubated for 4 days and the MFI of eGFP was deter-
mined via flow cytometer.
Murine BM transplantation. C57BL/6 mice were bred and maintained in 
the specific pathogen-free barrier facilities at Seattle Children’s Research 
Institute. Animal studies were carried out according to the guidelines 
of Seattle Children’s Research Institute Institutional Animal Care and 
Use Committee. BM from 6 to 8 weeks mice was harvested and Lin− 
cells were obtained using EasySep Mouse Hematopoietic Progenitor 
Cell Enrichment kit according to manufacture’s instruction (StemCell 
Technologies, Vancouver, BC), transduced overnight in media (StemSpan 
SFEM, StemCell Technologies) containing mSCF and mTPO (10 μg/ml; 
PeproTech, Rocky Hills, NJ) with the indicated LV overnight with 4 μg/
ml polybrene. Cells were washed, counted, and 1 × 106 transduced cells 
were transplanted into mice receiving 2 × 500 Gy total body irradiation 
conditioning. Recipient mice were evaluated by serial peripheral blood 
analyses beginning at 5 weeks, and cohorts were sacrificed at 24–26 weeks 
for detailed analyses.
Cord blood CD34+ cell isolation, transduction, and transplantation 
of NSG recipients. Human umbilical cord blood was obtained from the 
Puget Sound Blood Center cord blood donor program and CD34+ cells 
were isolated using Miltenyi CD34+ beads (Miltenyi, Biotec, Germany) 
according to the manufacturer’s instructions. Purity of CD34+Lineage− 
cells was >90% in all experiments. CD34+ cells were incubated for 8–12 
hours in IMDM with human cytokines (100 ng/ml SCF, TPO, and FLT3-L; 
PeproTech) and 5% fetal bovine serum. After incubation, cells were trans-
duced with the indicated LV at an multiplicity of infection of 10 for 8 hours 
in media with cytokines and 4 μg/ml polybrene. Transduced CD34+ cells 
were washed and transplanted into NOD/SCID/cγ−/− (NSG) mice. For all 
experiments, 6–12 weeks recipient mice were conditioned with 250 cGy 
total body irradiation and transplanted with 2–3 × 105 transduced, or mock 
transduced, CD34+ cells via retro-orbital injection. Peripheral blood sam-
ples were obtained from recipients 8 weeks after transplantation and the 
level of HSC engraftment was accessed via CD45 expression. Cohorts were 
sacrificed at 20–30 weeks for detailed FACS analysis of BM and spleen.
Flow cytometric analysis. Single-cell suspensions prepared from BM or 
spleen were incubated in phosphate-buffered saline with 3% fetal calf 
serum and fluorochrome-conjugated antibodies for 20 minutes at 4 °C, 
and washed twice before resuspension in phosphate-buffered saline with 
3% fetal calf serum for acquisition. The following antibodies were used: 
antihuman CD19, CD33, CD45, IgM, IgD, 38, CD24, CD10, CD34, anti-
mouse CD3, CD4, CD8, B220, CD21, CD24, CD43, IgM, IgD, Gr-1, 
CD11b, and CD45.1 (BD Biosciences, San Jose, CA and eBioscience, San 
Diego, CA). Cell analysis were performed using FACSCalibur, Aria II, and 
LSRII flow cytometers (BD Biosciences) and FlowJo software (Tree Star, 
Ashland, OR).
Viral copy number determination. Quantification of viral integration was 
adapted from a previously described protocol.5 Briefly, genomic DNA was 
obtained from spleen or total BM from sacrificed animals. Gag-specific 
primer/probe sets were used to amplify viral integrations in both mouse 
and human cells. To normalize DNA content in mouse cells, a murine 
β-actin primer/probe set was used; in human cells, a human RNaseP 
primer probe set was used (Applied Biosytems, Carlsbad, CA). Viral-
integration number was determined via a standard curve established using 
genomic DNA extracted from A20 murine B cell line or Nalm6 human B 
cell line, each containing a single LV integration.
Statistical analysis. Statistical analyses of relative eGFP marking and viral 
copy numbers were carried out using a two-tailed paired Student’s t test 
comparing the indicated cell populations from the groups of experimental 
mice or cell lines.
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suPPleMentarY MaterIal
Figure S1. Comparison of EμS.CD19, EμL.CD19, and EμB29 LV activ-
ity in human B cell lines.
Figure S2. Representative FACS plots from independent experiments 
shown in Figures 3 and 7.
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